Efficacy News and Research

RSS

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'

7 Apr 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

HemoShear, LLC, is pleased to announce that it was awarded a Phase 1 Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

FDA approves Covidien's PMA application for Pipeline Embolization Device

Covidien, a leading global provider of healthcare products, today announced that it received Premarket Approval from the U.S. Food and Drug Administration for the Pipeline Embolization Device, indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments.

7 Apr 2011

Superbugs and antibiotic resistance

Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.

6 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

Celldex Therapeutics, Inc. today announced that new data on its preclinical therapeutic antibody program, CDX-1127, is being presented in a poster presentation at the 2011 American Association for Cancer Research 102nd Annual Meeting in Orlando, FL.

6 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

6 Apr 2011

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services unit has formed a research collaboration with Denver-based Catholic Health Initiatives, one of the nation's largest health systems.

6 Apr 2011

OSU chemist developing solution to nerve agent exposure

Scientists are working to develop a new drug that will regenerate a critical enzyme in the human body that “ages” after a person is exposed to deadly chemical warfare agents.

5 Apr 2011

Insurance payers extend coverage for PTNS using Uroplasty's Urgent PC Neuromodulation System for OAB

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that two private insurance payers have elected to cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder (OAB) and associated symptoms.

5 Apr 2011

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease.

5 Apr 2011

Antimicrobial copper can effectively prevent MRSA in hospitals

A live broadcast from the University of Southampton today highlighted the effectiveness of antimicrobial copper in preventing the spread of antibiotic-resistant organisms, such as MRSA, in hospitals.

5 Apr 2011

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

Efficacy News and Research

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

FDA approves Covidien's PMA application for Pipeline Embolization Device

Superbugs and antibiotic resistance

Record number of medicines for various cancers in clinical trials

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

OSU chemist developing solution to nerve agent exposure

Insurance payers extend coverage for PTNS using Uroplasty's Urgent PC Neuromodulation System for OAB

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Antimicrobial copper can effectively prevent MRSA in hospitals

Scientists discover new compounds that may help fight against parasitic diseases

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News